Biopharmaceutics & Drug disPosition

Article	Citations
Physiological‐based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20‐years; in‐depth analysis of applications, organizations, and platforms	69
Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity	25
Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: Midazolam	14
Physiologically‐based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment	14
Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help	11
Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women	10
Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling	10
Concomitant lansoprazole ameliorates cisplatin‐induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats	10
In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies	10
Across‐species meta‐analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches	9
Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives	9
Inhibition of human UDP‐glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug–drug interactions	9
When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations	8
Comparative in silico prediction of P‐glycoprotein‐mediated transport for 2010–2020 US FDA‐approved drugs using six Web‐tools	8
Favipiravir biotransformation in liver cytosol: Species and sex differences in humans, monkeys, rats, and mice	8
Self‐emulsifying drug delivery system of (R)‐α‐lipoic acid to improve its stability and oral absorption	7
Effects of low temperature on blood‐to‐plasma ratio measurement	7
Characterization of red ginseng–drug interaction by CYP3A activity increased in high dose administration in mice	7
Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous β‐amyloid peptide accumulation in mice	6
Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator	6
The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery	6
The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study	6
Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs	5
Non‐clinical characterization of the disposition of EMA401, a novel small molecule angiotensin II type 2 receptor (AT2R) antagonist	5
Recent advances in the in vitro and in vivo methods to assess impact of P‐glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition	5

Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates—The impact of metabolising enzyme ontogeny and reduced cardiac output	5
Mechanistic evaluation of the effect of sodium‐dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacol	5
Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling	4
In‐depth analysis of patterns in selection of different physiologically based pharmacokinetic modeling tools: Part I – Applications and rationale behind the use of open source‐code software	4
Comparison of tissue pharmacokinetics of esflurbiprofen plaster with flurbiprofen tablets in patients with knee osteoarthritis: A multicenter randomized controlled trial	4
In‐depth analysis of patterns in selection of different physiologically‐based pharmacokinetic modeling tools: Part II — Assessment of model reusability and comparison between open and non‐open source‐	4
In vitro and in silico interactions of antiulcer, glucocorticoids and urological drugs on human carbonic anhydrase I and II isozymes	4
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3‐selective GABAkine KRM‐II‐81	4
Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder	4
In vivo monitoring of brain pharmacokinetics and pharmacodynamics with cerebral open flow microperfusion	4
Prediction of a clinically effective dose of THY1773, a novel V1Breceptor antagonist, based on preclinical data	4
Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients	4
Absorption, tissue disposition, and excretion of fasudil hydrochloride, a RHO kinase inhibitor, in rats and dogs	3
Absorption, metabolism, and pharmacokinetic profile of xanthohumol in rats as determined via UPLC‐MS/MS	3
In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose‐to‐brain drug delivery	3
Lisdexamfetamine and amphetamine pharmacokinetics in oral fluid, plasma, and urine after controlled oral administration of lisdexamfetamine	3
Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward	3
Model‐informed drug development: The mechanistic HSK3486 physiologically based pharmacokinetic model informing dose decisions in clinical trials of specific populations	3
Effect of hepar‐protecting Wuzhi capsule on pharmacokinetics and dose‐effect character of tacrolimus in healthy volunteers	3
Changes in uridine 5′‐diphospho‐glucuronosyltransferase 1A6 expression by histone deacetylase inhibitor valproic acid	3
Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients	3
Effects of aged garlic and ginkgo biloba extracts on the pharmacokinetics of sofosbuvir in rats	3
Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure	3
Fluorouracil uptake in triple‐negative breast cancer cells: Negligible contribution of equilibrative nucleoside transporters 1 and 2	3
Physiologically based pharmacokinetic model to predict drug concentrations of breast cancer resistance protein substrates in milk	3
Cytochrome P450 expression patterns in human osteoblasts during osteogenic differentiation with or without TNFα treatment	3
Pharmacodynamics‐based approach for efficacious human dose projection of BMS‐986260, a small molecule transforming growth factor beta receptor 1 inhibitor	2
Prediction of basic drug exposure in milk using a lactation model algorithm integrated within a physiologically based pharmacokinetic model	2
Physiologically‐based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans	2
Hepatic transporter‐mediated pharmacokinetic drug–drug interactions: Recent studies and regulatory recommendations	2
Exploring in vitro solubility of lamotrigine in physiologically mimetic conditions to prospect the in vivo dissolution in pediatric population	2
A novel semi‐mechanistic tumor growth fraction model for translation of preclinical efficacy of anti‐glypican 3 antibody drug conjugate to human	2
Profiling pharmacokinetics of double‐negative T cells and cytokines via a single intravenous administration in NSG mice	2
Biopharmaceutical characterization of a novel sustained‐release formulation of allopurinol with reduced nephrotoxicity	2
Achieving a low human dose for targeted covalent drugs: Pharmacokinetic and pharmacodynamic considerations on target characteristics and drug attributes	2
Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l‐lactate transport in the hepatocellular carcinoma cell line	2
Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells	2
In vitro evaluation of 99mTc‐sultamicillin for infection imaging	2
Deoxyshikonin reversibly inhibits cytochrome P450 2B6	2
Regional distributions of curcumin and tetrahydrocurcumin in the liver and small intestine of rats when orally co‐administered with quercetin and paeoniflorin	2
Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds	2
Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non‐valvular atrial fibrillation	2
Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats	2
Develop adult extrapolation to pediatrics and pediatric dose optimization based on the physiological pharmacokinetic model of azithromycin	2
Enhanced oral bioavailability of capsaicin‐loaded microencapsulation complex via electrospray technology: Preparation, in vitro and in vivo evaluation	2
Selective inhibitory effects of HYIpro‐3‐1 on CYP1A2 in human liver microsomes	2
Decreased plasma acetaminophen glucuronide/acetaminophen concentration ratio warns the onset of acetaminophen‐induced liver injury	2
Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia	1
Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT6 receptor occupancy from non‐human primates to humans	1
Vicagrel is hydrolyzed by Raf kinase inhibitor protein in human intestine	1

Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry	1
Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling	1
In vitro–in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapo	1
Evaluation on absorption risks of amentoflavone after oral administration in rats	1
Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model	1
Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug‐resistant tuberculosis therapy	1
Pharmacokinetics of eperisone following oral administration in healthy Korean volunteers	1
Computational exploration of microsomal cytochrome P450 3A1 enzyme modulation by phytochemicals of Cichorium intybus L.: Insights into drug metabolism	1
Evaluation of bottom‐up modeling of the blood–brain barrier to improve brain penetration prediction via physiologically based pharmacokinetic modeling	1
Metabolic interaction between biflavonoids in Ginkgo biloba leaves and tacrolimus	1
Optimizing transcardial perfusion of small molecules and biologics for brain penetration and biodistribution studies in rodents	1
Drug‐drug interaction between diclofenac and gamma‐hydroxybutyric acid	1
Issue Information	0
Issue Information	0
In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine	0
	0
Association between α‐defensin 5 and the expression and function of P‐glycoprotein in differentiated intestinal Caco‐2 cells	0
Issue Information	0
Issue Information	0
Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained‐release formulations	0
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study	0
Issue Information	0
Corrigendum	0
Comparison of biomarker and chromatographic analytical approaches to pharmacokinetic study of sitagliptin	0
Issue Information	0
Intestinal absorption pathways of lisinopril: Mechanistic investigations	0
	0
	0
Irinotecan‐induced gastrointestinal damage alters the expression of peptide transporter 1 and absorption of cephalexin in rats	0
	0
Issue Information	0
	0
Linking in vitro–in vivo extrapolations with physiologically based modeling to inform drug and formulation development	0
Can a monthly exenatide extended release regimen provide a therapeutic and cost benefit?	0
Issue Information	0
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells	0
Issue Information	0
	0
Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK‐448, for its anti‐tumor efficacy in a rat xenograft model	0
Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage	0
Applicability of the Øie‐Tozer model to predict three types of distribution volume (Vd) in humans: Vd in central compartment, Vd at steady state, and Vd at beta phase	0
Issue Information	0
	0
Enalapril increases the urinary excretion of metformin in rats by inducing multidrug and toxin excretion protein 1 in the kidney	0
Special issue on applications of in vitro, in vivo, and modeling and simulation tools for central nervous system drug disposition	0
	0
Issue Information	0
Quantitative analysis of the impact of membrane permeability on intestinal first‐pass metabolism of CYP3A substrates	0
Issue Information	0
Issue Information	0
Population analysis to assess the influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in New Zealand White rabbits	0
Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel	0
Issue Information	0
	0
	0
	0
Self‐micellizing solid dispersion of tacrolimus: Physicochemical and pharmacokinetic characterization	0
Febuxostat and its major acyl glucuronide metabolite are potent inhibitors of organic anion transporter 3: Implications for drug‐drug interactions with rivaroxaban	0
	0
	0
Issue Information	0
Nanocrystal solid dispersion of fuzapladib free acid with improved oral bioavailability	0
Issue Information	0
	0
	0
	0
Identification and characterization of an endogenous biomarker of the renal vectorial transport (OCT2‐MATE1)	0
Influence of piperine and omeprazole on the regional absorption of Daclatasvir from rabbit intestine	0
Issue Information	0
Issue Information	0
	0
Special issue on applications of modeling and simulation in pharmaceutical drug development	0
Issue Information	0
	0
Metabolism and pharmacokinetic study of deuterated osimertinib	0
Characterization of AST‐001 non‐clinical pharmacokinetics: A novel selective AKR1C3‐activated prodrug in mice, rats, and cynomolgus monkeys	0
Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants	0
Estimation of fraction of drug metabolism by a single UDP‐glucuronosyl transferase enzyme using relative expression factor	0
Issue Information	0
Issue Information	0

Utility of cystatin C and serum creatinine‐based glomerular filtration rate equations in predicting vancomycin clearance: A population pharmacokinetics analysis in elderly Chinese patients	0
	0
Interspecies differences on pharmacokinetics of rebamipide following oral administration to rats and dogs	0
Evaluation of bleeding and anticoagulation markers by edoxaban and low‐dose cyclosporine: A case series study	0
Issue Information	0
	0
	0
	0
	0
Issue Information	0
Attenuation of phenobarbital‐induced cytochrome P450 expression in carbon tetrachloride‐induced hepatitis in mice models	0
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs	0
Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐267	0
	0
Pharmacokinetic–pharmacodynamic modeling for hepatic delivery and efficacy of antisense oligonucleotides with lipophilic ligands in mice	0
	0
Pharmacokinetic–pharmacodynamic modeling of the active components of Shenkang injection in rats with chronic renal failure and its protective effect on damaged renal cells	0
Selective inhibitory effects of suberosin on CYP1A2 in human liver microsomes	0
Issue Information	0
Issue Information	0
Influence of Gegenqinlian decoction on pharmacokinetics and pharmacodynamics of saxagliptin in type 2 diabetes mellitus rats	0